Author Archive for: admin Z.9

About admin Z.9

This author has not written his bio yet.
But we are proud to say that admin Z.9 contributed 1231 entries already.

Entries by admin Z.9

Re: The Protective Role of Coenzyme Q10 in Renal Injury Associated with Extracorporeal Shock Wave Lithotripsy: a Randomized, Placebo Controlled Clinical Trial

Sir, We read the article by Carrasco et al. [1] with interest. The study is worth attention as it relates to short-term CoQ10 use to prevent renal damage caused by SWL. However, some conflicting points and omissions occur. In addition, it would have been more ethically appropriate to conduct an animal study. There are studies on the […]

What’s the diagnosis?

Test yourself against our experts with our weekly quiz. You can type your answers here if you want to compare with our answers, or just click the ‘submit’ button below. No such quiz/survey/poll

Video: Move over fluoroscopy: ultrasound-guided PCNL is just as good

Percutaneous nephrolithotomy guided solely by ultrasonography: a 5-year study of >700 cases Song Yan, Fei Xiang and Song Yongsheng Division of Urology, Sheng Jing Hospital, China Medical University, Shenyang, China OBJECTIVE • To evaluate the safety and efficacy of percutaneous nephrolithotomy (PCNL) solely guided by ultrasonography (US). PATIENTS AND METHODS • From May 2007 to July 2012, […]

Picture Quiz

Test yourself against our experts with our weekly quiz. You can type your answers here if you want to compare with our answers, or just click the ‘submit’ button below. Image from Gao X, Pang J, Si-tu J et al. BJU Int 2013; 112: 944–952. No such quiz/survey/poll

Prospective randomized double-blind multicenter phase II study comparing chemotherapy with gemcitabine and cisplatin plus sorafenib vs gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer – SUSE – (AUO-AB 31/05)

Sir, Krege et al. [1] report on the results of adding sorafenib to standard cisplatin and gemcitabine (CG) in first-line advanced urothelial cancer. Despite reporting on negative findings overall, the results should be discussed because of two major issues. Firstly, investigators are now asked to delineate the mechanisms behind the clinical benefit of specific targeted […]

© 2025 BJU International. All Rights Reserved.